午夜插插,噜噜噜影院,啪啪伊人网,欧美熟夫,景甜吻戏视频,男人强操性感蕾丝美女视频在线网站,日本美女跳舞视频

ChemicalBook >> journal list >> Acta Anaesthesiologica Scandinavica >>article
Acta Anaesthesiologica Scandinavica

Acta Anaesthesiologica Scandinavica

IF: 1.89
Download PDF

Pharmacokinetic implications for the clinical use of atropine, scopolamine and glycopyrrolate.

Published:1 February 1988 DOI: 10.1111/j.1399-6576.1988.tb02691.x PMID: 3279717
J Kanto, U Klotz

Abstract

Several specific and sensitive new methods for determining atropine and its metabolites in biological fluids have increased the possibility to characterise the pharmacokinetic properties of this antimuscarinic agent. Following i.v. injection, atropine disappears very quickly from the circulation, resembling its fast onset of action. Age, but not sex, appears to have a clear effect on its kinetics, explaining at least partly the higher sensitivity of very young and very old patients to this anticholinergic agent. Following i.m. or oral atropine administration, typical anticholinergic effects coincide quite well with the absorption rate of the drug, indicating that the premedication should be given about 1 and 2 h before induction of anaesthesia. A sufficient absorption after rectal administration offers an alternative treatment, especially in children. Differing from its placental transfer, atropine has a delayed and incomplete lumbar cerebrospinal fluid penetration, indicating a fundamental difference between these two biological membranes. Oropharyngeally administered atropine has a very variable absorption, but inhaled or intratracheally given drug has produced interesting new results, e.g. pulmonary atropine administration appears to have clinical significance in special situations, such as cardiac arrest and organophosphate poisoning (military personnel). Depending on the method used, different data on the metabolism and excretion for atropine have been reported and therefore further studies are needed in this respect. The pharmacokinetics of scopolamine and glycopyrrolate and their relation to clinical response are poorly understood.

Substances (3)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Glycopyrrolate 596-51-0 C19H28BrNO3- 485 suppliers $10.00-$1500.00
Atropine 51-55-8 C17H23NO3 268 suppliers $22.40-$1697.85
Scopolamine 51-34-3 C17H21NO4 187 suppliers $60.00-$40480.00

Similar articles

IF:0

Clinical use of hydroxyethyl starch and serious adverse effects: Need for awareness amongst the medical fraternity

Medical Journal Armed Forces India Surg Vice Adm Sushil Kumar AVSM, NM,etc Published: 1 July 2014
IF:4.3

A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.

ACS Applied Electronic Materials Noemi Lois, Evie Gardner,etc Published: 14 July 2020